{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:35:23Z","timestamp":1775453723077,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Deutsche Dermatologische Gesellschaft"},{"name":"Deutsche Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie"},{"name":"Paul Ehrlich Gesellschaft"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13643-016-0251-3","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T08:36:55Z","timestamp":1462264615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of pharmacological agents in the treatment of erythema migrans in early Lyme borreliosis\u2014systematic review protocol"],"prefix":"10.1186","volume":"5","author":[{"given":"Gabriel","family":"Torbahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidelore","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Allert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Dersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Fingerle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harriet","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Motschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg J.","family":"Meerpohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,3]]},"reference":[{"key":"251_CR1","first-page":"w13725","volume":"143","author":"E Altpeter","year":"2013","unstructured":"Altpeter E et al. Tick related diseases in Switzerland, 2008 to 2011. Swiss Med Wkly. 2013;143:w13725.","journal-title":"Swiss Med Wkly"},{"issue":"10","key":"251_CR2","first-page":"1","volume":"57","author":"RM Bacon","year":"2008","unstructured":"Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease\u2014United States, 1992-2006. MMWR Surveill Summ. 2008;57(10):1\u20139.","journal-title":"MMWR Surveill Summ"},{"issue":"20","key":"251_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJM199511163332004","volume":"333","author":"J Berglund","year":"1995","unstructured":"Berglund J et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med. 1995;333(20):1319\u201327.","journal-title":"N Engl J Med"},{"key":"251_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000213069","volume":"37","author":"Z Hubalek","year":"2009","unstructured":"Hubalek Z. Epidemiology of lyme borreliosis. Curr Probl Dermatol. 2009;37:31\u201350.","journal-title":"Curr Probl Dermatol"},{"issue":"10","key":"251_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s100960050381","volume":"18","author":"HI Huppertz","year":"1999","unstructured":"Huppertz HI et al. Incidence of Lyme borreliosis in the Wurzburg region of Germany. Eur J Clin Microbiol Infect Dis. 1999;18(10):697\u2013703.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"251_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/1469-0691.12532","volume":"20","author":"XB Ni","year":"2014","unstructured":"Ni XB et al. Lyme borreliosis caused by diverse genospecies of Borrelia burgdorferi sensu lato in northeastern China. Clin Microbiol Infect. 2014;20(8):808\u201314.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"251_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2340\/00015555-1549","volume":"93","author":"P Eriksson","year":"2013","unstructured":"Eriksson P et al. The many faces of solitary and multiple erythema migrans. Acta Derm Venereol. 2013;93(6):693\u2013700.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"251_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00105-011-2256-0","volume":"63","author":"H Hofmann","year":"2012","unstructured":"Hofmann H. The variable spectrum of cutaneous Lyme borreliosis. Diagnosis and therapy. Hautarzt. 2012;63(5):381\u20139.","journal-title":"Hautarzt"},{"issue":"18","key":"251_CR9","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1056\/NEJMcp1314325","volume":"370","author":"ED Shapiro","year":"2014","unstructured":"Shapiro ED. Clinical practice. Lyme disease. N Engl J Med. 2014;370(18):1724\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"251_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","volume":"17","author":"G Stanek","year":"2011","unstructured":"Stanek G et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17(1):69\u201379.","journal-title":"Clin Microbiol Infect"},{"key":"251_CR11","unstructured":"Centers for Disease Control and Prevention. Clinical manifestations of confirmed lyme disease cases\u2014United States, 2001-2010. Available from: \n                    http:\/\/www.cdc.gov\/lyme\/stats\/chartstables\/casesbysymptom.html\n                    \n                  . Accessed 29 Oct 2015."},{"key":"251_CR12","unstructured":"Centers for Disease Control and Prevention. Signs and symptoms of untreated lyme disease. Available from: \n                    http:\/\/www.cdc.gov\/lyme\/signs_symptoms\/index.html\n                    \n                  . Accessed 16 Nov 2015."},{"issue":"6","key":"251_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-136-6-200203190-00012","volume":"136","author":"RB Nadelman","year":"2002","unstructured":"Nadelman RB, Wormser GP. Recognition and treatment of erythema migrans: are we off target? Ann Intern Med. 2002;136(6):477\u20139.","journal-title":"Ann Intern Med"},{"issue":"6","key":"251_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-136-6-200203190-00005","volume":"136","author":"RP Smith","year":"2002","unstructured":"Smith RP et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med. 2002;136(6):421\u20138.","journal-title":"Ann Intern Med"},{"issue":"2","key":"251_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399404007276","volume":"6","author":"PG Auwaerter","year":"2004","unstructured":"Auwaerter PG, Aucott J, Dumler JS. Lyme borreliosis (Lyme disease): molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment. Expert Rev Mol Med. 2004;6(2):1\u201322.","journal-title":"Expert Rev Mol Med"},{"key":"251_CR16","unstructured":"Centers for Disease Control and Prevention. Lyme disease (Borrelia burgdorferi) - 2011 Case Definition Available from: \n                    https:\/\/wwwn.cdc.gov\/nndss\/conditions\/lyme-disease\/case-definition\/2011\/\n                    \n                  . Accessed 21 Mar 2016."},{"key":"251_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000213070","volume":"37","author":"F Strle","year":"2009","unstructured":"Strle F, Stanek G. Clinical manifestations and diagnosis of lyme borreliosis. Curr Probl Dermatol. 2009;37:51\u2013110.","journal-title":"Curr Probl Dermatol"},{"issue":"9","key":"251_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1086\/508667","volume":"43","author":"GP Wormser","year":"2006","unstructured":"Wormser GP et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(9):1089\u2013134.","journal-title":"Clin Infect Dis"},{"key":"251_CR19","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S1-Leitlinie: Kutane Manifestationen der Lyme Borreliose. 01.02.2009 [in \u00dcberarbeitung]. Available from: \n                    http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-044_abgelaufen_01.pdf\n                    \n                  . Accessed 28 Mar 2016."},{"issue":"9","key":"251_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1586\/14787210.2014.940900","volume":"12","author":"DJ Cameron","year":"2014","unstructured":"Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti-Infect Ther. 2014;12(9):1103\u201335.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"251_CR21","unstructured":"Deutsche Borreliose Gesellschaft. Diagnostik und Therapie der Lyme-Borreliose - Leitlinien der Deutschen Borreliose-Gesellschaft [Mai 2011]. Available from: \n                    http:\/\/www.borreliose-gesellschaft.de\/Texte\/Leitlinien.pdf\n                    \n                  . Accessed 28 Mar 2016."},{"issue":"8728","key":"251_CR22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/0140-6736(90)93103-V","volume":"336","author":"RJ Dattwyler","year":"1990","unstructured":"Dattwyler RJ et al. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336(8728):1404\u20136.","journal-title":"Lancet"},{"issue":"9","key":"251_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-124-9-199605010-00002","volume":"124","author":"BJ Luft","year":"1996","unstructured":"Luft BJ et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996;124(9):785\u201391.","journal-title":"Ann Intern Med"},{"key":"251_CR24","volume-title":"Critical needs and gaps in understanding prevention, amelioration, and resolution of lyme and other tick-borne diseases: the short-term and long-term outcomes: workshop report","author":"IOM","year":"2011","unstructured":"IOM. Critical needs and gaps in understanding prevention, amelioration, and resolution of lyme and other tick-borne diseases: the short-term and long-term outcomes: workshop report. Washington: National Academies Press (US). National Academy of Sciences; 2011."},{"issue":"9","key":"251_CR25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/ene.12744","volume":"22","author":"R Dersch","year":"2015","unstructured":"Dersch R et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis\u2014a systematic review. Eur J Neurol. 2015;22(9):1249\u201359.","journal-title":"Eur J Neurol"},{"key":"251_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/2046-4053-3-117","volume":"3","author":"R Dersch","year":"2014","unstructured":"Dersch R et al. Efficacy and safety of pharmacological treatments for neuroborreliosis\u2014protocol for a systematic review. Syst Rev. 2014;3:117.","journal-title":"Syst Rev"},{"key":"251_CR27","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"issue":"8","key":"251_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.zefq.2008.08.028","volume":"102","author":"G Gartlehner","year":"2008","unstructured":"Gartlehner G. Assessment of adverse effects and applicability\u2014two areas not (yet) covered adequately in Cochrane reports. Z Evid Fortbild Qual Gesundhwes. 2008;102(8):497\u2013502.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"5","key":"251_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jclinepi.2008.06.007","volume":"63","author":"R Chou","year":"2010","unstructured":"Chou R et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63(5):502\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"251_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"1","key":"251_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09638288.2013.775360","volume":"36","author":"L Turner-Stokes","year":"2014","unstructured":"Turner-Stokes L et al. The Neurological Impairment Scale: reliability and validity as a predictor of functional outcome in neurorehabilitation. Disabil Rehabil. 2014;36(1):23\u201331.","journal-title":"Disabil Rehabil"},{"issue":"5","key":"251_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC Swieten van","year":"1988","unstructured":"van Swieten JC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604\u20137.","journal-title":"Stroke"},{"key":"251_CR33","unstructured":"Review manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014."},{"key":"251_CR34","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from: \n                    http:\/\/handbook.cochrane.org\/\n                    \n                  . Accessed 16 Nov 2015."},{"key":"251_CR35","unstructured":"Sterne JAC, Higgins JPT, Reeves BC, on behalf of the development group for ACROBAT-NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-Randomized Studies of Interventions (ACROBAT-NRSI), Version 1.0.0, 24 September 2014. Available from: \n                    http:\/\/www.riskofbias.info\n                    \n                  . Accessed 16 Nov 2015."},{"issue":"1","key":"251_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2288-8-32","volume":"8","author":"JO Friedrich","year":"2008","unstructured":"Friedrich JO, Adhikari NK, Beyene J. The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol. 2008;8(1):32.","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"251_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt GH et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles\u2014continuous outcomes. J Clin Epidemiol. 2013;66(2):173\u201383.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"251_CR38","doi-asserted-by":"publisher","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","volume":"8","author":"EA Akl","year":"2013","unstructured":"Akl EA et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One. 2013;8(2):e57132.","journal-title":"PLoS One"},{"issue":"9","key":"251_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jclinepi.2013.03.014","volume":"66","author":"S Ebrahim","year":"2013","unstructured":"Ebrahim S et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol. 2013;66(9):1014\u20131021.e1.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"251_CR40","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jclinepi.2013.11.014","volume":"67","author":"S Ebrahim","year":"2014","unstructured":"Ebrahim S et al. Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol. 2014;67(5):560\u201370.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"251_CR41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/sim.2639","volume":"26","author":"S Senn","year":"2007","unstructured":"Senn S. Trying to be precise about vagueness. Stat Med. 2007;26(7):1417\u201330.","journal-title":"Stat Med"},{"key":"251_CR42","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 9: analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011; Version 5.1.0 (updated March 2011). Available from: \n                    http:\/\/handbook.cochrane.org\/\n                    \n                  . Accessed 16 Nov 2015."},{"key":"251_CR43","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"key":"251_CR44","unstructured":"Oxford Centre for Evidence-based Medicine. Levels of Evidence (March 2009). Available from: \n                    http:\/\/www.cebm.net\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/\n                    \n                  . Accessed 16 Dec 2015."},{"issue":"4","key":"251_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"key":"251_CR46","volume-title":"Richtlijn Lymeziekte","author":"CBO","year":"2013","unstructured":"CBO. Richtlijn Lymeziekte. 2013."},{"issue":"60","key":"251_CR47","first-page":"925","volume":"2","author":"J Evison","year":"2006","unstructured":"Evison J et al. Lyme disease Part 2: clinic and treatment. Rev Med Suisse. 2006;2(60):925\u20138. 930-4.","journal-title":"Rev Med Suisse"},{"issue":"2","key":"251_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/00003495-199957020-00003","volume":"57","author":"PS Loewen","year":"1999","unstructured":"Loewen PS, Marra CA, Marra F. Systematic review of the treatment of early Lyme disease. Drugs. 1999;57(2):157\u201373.","journal-title":"Drugs"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-016-0251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-016-0251-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-016-0251-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-016-0251-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T13:12:53Z","timestamp":1487596373000},"score":1,"resource":{"primary":{"URL":"http:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-016-0251-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1186\/s13643-016-0251-3","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,3]]},"article-number":"73"}}